Dylan Dupuis

Stock Analyst at Roth MKM

(2.64)
# 2,003
Out of 5,128 analysts
8
Total ratings
50%
Success rate
43.19%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Dylan Dupuis

Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $28
Current: $1.90
Upside: +1,373.68%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $5.10
Upside: +115.69%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $40.00
Upside: -42.50%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $32.38
Upside: -1.17%